Skip to main content
ROQUEFORT THERAPEUTICS PLC logo

ROQUEFORT THERAPEUTICS PLC — Investor Relations & Filings

Ticker · ROQ ISIN · GB00BMDQ2T15 LEI · 254900P4SISIWOR9RH34 IL Professional, scientific and technical activities
Open in API
Filings indexed 182 across all filing types
Latest filing 2022-03-08 Major Shareholding Noti…
Country GB United Kingdom
Listing IL ROQ

About ROQUEFORT THERAPEUTICS PLC

https://www.roquefortplc.com/

Roquefort Therapeutics PLC is a biotechnology company focused on developing next-generation, first-in-class medicines for hard-to-treat cancers. The company operates within the high-growth immuno-oncology market. Its portfolio consists of five novel, patent-protected, pre-clinical anti-cancer programs. These programs are designed to target cancers that have become resistant to existing therapies. Roquefort Therapeutics utilizes a distributed R&D model, combining its in-house expertise and laboratory facilities with a network of partnerships with leading academic cancer research centers to advance its development strategy.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains fields related to 'acquisition or disposal of voting rights', 'shareholder(s)', and 'Total positions of person(s) subject to the notification obligation', showing a change in percentage holding (from 8.34% to 9.04%). This structure is characteristic of regulatory filings concerning significant changes in share ownership. The presence of 'RNS Number' and the reference to the 'FCA' (Financial Conduct Authority) confirms it is a regulatory disclosure. Since the filing specifically reports a change in major shareholding, the most appropriate code is 'MRQ' (Major Shareholding Notification).
2022-03-08 English
Appointment of Strategic & Scientific Advisor
Regulatory Filings Classification · 98% confidence The document is a formal announcement released via RNS (RNS Number: 4842B) on February 14, 2022. The core content announces the 'Appointment of Strategic & Scientific Advisor,' Professor Trevor M. Jones CBE FMedSci, to the Board of Roquefort Therapeutics plc. This type of announcement, detailing changes in senior personnel or advisors, directly corresponds to the definition of Board/Management Information (MANG). Although it is distributed via RNS, the specific nature of the content (management change) makes MANG a more precise classification than the general fallback RNS. The document length (6106 chars) is substantial enough that it is the primary announcement, not just a placeholder for a report.
2022-02-14 English
Holding(s) in Company
Director's Dealing Classification · 98% confidence The document is identified by the header 'RNS Number : 0485B' and contains the standard form 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, specifically detailing the acquisition or disposal of voting rights that cross a notification threshold. This directly corresponds to the definition of a Major Shareholding Notification (MRQ). Although it is distributed via RNS, the content is specific enough to warrant the MRQ classification over the general RNS fallback.
2022-02-08 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and is issued via 'RNS Number : 9026Z' by Roquefort Therapeutics PLC. It details changes in voting rights percentages (crossing thresholds from 6.25% to 7.09%) by a specific shareholder (Abdelatif LACHAB). This type of filing, which reports changes in significant share ownership, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the content is specific enough to warrant the MRQ classification over the general RNS fallback.
2022-01-28 English
Director/PDMR Shareholding
Director's Dealing Classification · 99% confidence The document is titled 'Director/PDMR Shareholding' and details the purchase of ordinary shares by Stephen West, the Executive Chairman. It explicitly mentions the transaction details, resulting holdings, and includes a formal 'NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM' section, which is characteristic of insider trading or director dealing disclosures required by market regulators (like UK MAR). This directly corresponds to the definition of Director's Dealing (Code: DIRS). The presence of the RNS Number and LSE context confirms it is a regulatory announcement, but the specific content points to DIRS over the general RNS fallback.
2022-01-19 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is identified by the header 'RNS Number : 9454Y' and contains the standard form 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, specifically detailing the acquisition or disposal of voting rights that cross a notification threshold. This directly corresponds to the definition of a Major Shareholding Notification (MRQ). Although it is distributed via RNS, the content itself is a specific regulatory disclosure about share ownership changes, making MRQ the most precise classification over the general RNS fallback.
2022-01-19 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.